Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Market Performance - The pharmaceutical commercial sector increased by 1.32% on January 9, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers - RunDa Medical (603108) closed at 17.94, up 9.99% with a trading volume of 846,200 shares [1] - Huaren Health (301408) closed at 22.17, up 9.97% with a trading volume of 627,800 shares [1] - Shangyu Pingmin (301017) closed at 17.24, up 7.75% with a trading volume of 336,500 shares [1] Other Notable Stocks - Zhongyao Holdings (000950) closed at 6.31, up 5.87% with a trading volume of 1,147,000 shares [1] - Saily Medical (603716) closed at 27.83, up 4.39% with a trading volume of 783,100 shares [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 122 million yuan from institutional investors and 174 million yuan from speculative funds, while retail investors saw a net inflow of 296 million yuan [2] - The trading volume and turnover for various stocks indicate a mixed sentiment among different investor categories [2] Individual Stock Fund Flow - RunDa Medical had a net inflow of 2.30 billion yuan from institutional investors, while it faced a net outflow of 1.36 billion yuan from speculative funds [3] - Zhongyao Holdings saw a net inflow of 61.04 million yuan from institutional investors, with a net outflow of 62.93 million yuan from retail investors [3] - The overall fund flow indicates varying levels of confidence among different investor types in the pharmaceutical sector [3]

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2026-004 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于为下属控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 广西南宁柳药药业有限公司（简称"南宁柳药"） | | --- | --- | --- | --- | --- | | 担保 | 本次担保金额 | 3,200.00 | 万元 | | | 对象一 | 实际为其提供的担保余额 | 122,822.35 | | 万元（含本次） | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | | 被担保人名称 | | | 广西玉林柳药药业有限公司（简称"玉林柳药"） | | | 本次担保金额 | 2,0 ...

Core Viewpoint - The announcement details the maturity and redemption of the "Liuyao Convertible Bonds," including the timeline for trading suspension and the redemption amount for bondholders [2][4]. Group 1: Bond Details - The "Liuyao Convertible Bonds" were issued on January 16, 2020, with a total amount of 802.20 million yuan and a maturity period of six years, ending on January 15, 2026 [2][3]. - The redemption price for the bonds at maturity will be 108 yuan per bond, which includes the final interest payment [4][5]. - The last trading day for the bonds is January 12, 2026, and they will stop trading on January 13, 2026 [3][4]. Group 2: Redemption and Taxation - The redemption and payment of principal and interest will occur on January 16, 2026, with the funds being transferred to the bondholders' accounts by the China Securities Depository and Clearing Corporation [5][6]. - Individual investors will have a net payout of 106.40 yuan per bond after a 20% tax deduction on the interest income, while non-resident enterprises will receive 107.20 yuan per bond after a 10% tax deduction [6][7].

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2026-003 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于"柳药转债"到期兑付暨摘牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因"柳药转债"到期兑付暨摘牌，广西柳药集团股份有限公司（以下简称"公 司"）的相关证券停复牌情况如下： 自 2026 年 1 月 13 日至 2026 年 1 月 15 日，"柳药转债"持有人仍可依据约 定的条件将"柳药转债"转化为公司股票。 经中国证券监督管理委员会证监许可[2019]2303 号文核准，公司于 2020 年 1 月16 日公开发行 802.20 万张可转换公司债券，每张面值 100 元，发行总额 80,220.00 万元，期限为 6 年（即 2020 年 1 月 16 日至 2026 年 1 月 15 日）。经上海证券交易 所自律监管决定书[2020]53 号文同意，公司 8 ...

Group 1 - The company, Liu Pharmaceutical Group, announced on January 5 that it has repurchased a total of 10.803 million shares through centralized bidding, which represents 2.72% of the company's total share capital, an increase of 0.26% compared to the last repurchase progress announcement [1] - The highest price for the repurchased shares was 19.07 yuan per share, while the lowest price was 17.83 yuan per share, with a total amount spent of approximately 199 million yuan [1] Group 2 - The news highlights the rapid sell-out of 1499 yuan Feitian Moutai on the iMoutai App, which has surged to the top of the Apple shopping chart, with 100,000 users placing orders [1] - The distributors are offering the same price as a reward, and 1,000 boxes were quickly sold out [1]

格隆汇1月5日丨柳药集团(603368.SH)公布，截至2025年12月31日，公司通过集中竞价交易方式回购股 份数量为1,080.30万股，已回购股份占公司目前总股本的比例为2.72%，较上次回购进展公告披露数相 比增加0.26%，回购成交的最高价为19.07元/股、最低价为17.83元/股，已支付的总金额为19,863.82万元 （不含交易费用）。 ...

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2026-002 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于以集中竞价交易方式股份回购的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 7 月 7 | 25 | 日~2026 | 年 | 月 | 24 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 1,080.30万股 | | | | | | | 累计已回购股数占总股本比例 | 2.72% | | ...

证券代码：603368 证券简称：柳药集团 公告编号：2026-001 转债代码：113563 转债简称：柳药转债 广西柳药集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 累计转股情况：截至 2025 年 12 月 31 日，累计人民币 454,000 元"柳 药转债"已转换成公司股份，占可转债发行总量的 0.0566%；累计转股数量为 19,447 股，占可转债转股前公司发行股份总额的 0.0054%。 ● 未转股可转债情况：截至 2025 年 12 月 31 日，尚未转股的"柳药转债" 金额为人民币 801,746,000 元，占可转债发行总量的 99.9434%。 一、可转债发行上市概况 经中国证券监督管理委员会《关于核准广西柳州医药股份有限公司公开发行 可转换公司债券的批复》（证监许可[2019]2303 号）核准，广西柳药集团股份有 限公司（以下简称"公司"）于 2020 年 1 月 16 日公开发行 802.20 万张可转换 公司债券，每张面 ...